The 2-Minute Rule for ABBV-744 and other BRD4 inhibitors comparison
In Section C, members will obtain ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will acquire treatment until eventually ailment progression or the individuals are not able to tolerate the study drugs.then market H3K27Ac at this area. Chromatin hyperacetylation could enhance the accessibility